Integrated Filing — IndAS



General information about company
Scrip Code 500201
NSE Symbol INDIAGLYCO
MSEI Symbol NOTLISTED
ISIN INE560A01015
Name of company INDIA GLYCOLS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 07-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 31-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 07-Aug-2025   15:47:00
End date and time of board meeting 07-Aug-2025   17:00:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 25031200000
Other income 14000000
Total income 25045200000
2 Expenses
(a) Cost of materials consumed 6691000000
(b) Purchases of stock-in-trade 443400000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -359700000
(d) Employee benefit expense 310600000
(e) Finance costs 446800000
(f) Depreciation, depletion and amortisation expense 344500000
(f) Other Expenses
1 Excise Duty 14626600000 14626600000
2 Power and Fuel 915300000 915300000
3 Other Expenses 907600000 907600000
Total other expenses 16449500000
Total expenses 24326100000
3 Total profit before exceptional items and tax 719100000
4 Exceptional items 0
5 Total profit before tax 719100000
6 Tax expense
7 Current tax 75700000
8 Deferred tax 97100000
9 Total tax expenses 172800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 546300000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 186200000
16 Total profit (loss) for period 732500000
17 Other comprehensive income net of taxes -4300000
18 Total Comprehensive Income for the period 728200000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 732500000
Total profit or loss, attributable to non-controlling interests 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 728200000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0
21 Details of equity share capital
Paid-up equity share capital 309600000
Face value of equity share capital 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 23.66
Diluted earnings (loss) per share from continuing operations 23.66
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 23.66
Diluted earnings (loss) per share from continuing and discontinued operations 23.66
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Note on Financial Results: nAt point no.21 'Face value of equity share capital' of Rs.10 is the Face value per equity share. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Bio-based Specialities and Performance Chemicals 2999900000 2999900000
2 Potable Spirits 18050600000 18050600000
3 Ennature Biopharma 505000000 505000000
4 Bio-Fuel 3475700000 3475700000
Total Segment Revenue 25031200000
Less: Inter segment revenue 0 0
Revenue from operations 25031200000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Bio-based Specialities and Performance Chemicals 326000000 326000000
2 Potable Spirits 723300000 723300000
3 Ennature Biopharma 12000000 12000000
4 Bio-Fuel 226700000 226700000
Total Profit before tax 1288000000
i. Finance cost 446800000 446800000
ii. Other Unallocable Expenditure net off Unallocable income -64100000 -64100000
Profit before tax 905300000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Bio-based Specialities and Performance Chemicals 34387900000 34387900000
2 Potable Spirits 6013200000 6013200000
3 Ennature Biopharma 4515000000 4515000000
4 Bio-Fuel 12455600000 12455600000
Total Segment Asset 57371700000 57371700000
Un-allocable Assets 5070000000 5070000000
Net Segment Asset 62441700000 62441700000
4 Segment Liabilities
Segment Liabilities
1 Bio-based Specialities and Performance Chemicals 7676500000 7676500000
2 Potable Spirits 3392500000 3392500000
3 Ennature Biopharma 728400000 728400000
4 Bio-Fuel 935900000 935900000
Total Segment Liabilities 12733300000 12733300000
Un-allocable Liabilities 26421300000 26421300000
Net Segment Liabilities 39154600000 39154600000
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) Note for Segment results: nThe actual figures (Rs. in Crore) are as follows: n nfor Q1FY26: n n(a) Unallocable Corporate Expenses net off Unallocable income: 12.21 n(b) Share of profit/ (loss) of Joint Venture: 18.62 n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit and loss -3700000 -3700000
Total Amount of items that will not be reclassified to profit and loss -3700000
2 Income tax relating to items that will not be reclassified to profit or loss -900000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 1500000
5 Total Other comprehensive income -4300000